Brukinsa® (zanubrutinib) capsules, for oral use

CAPHOSOL® CAPHOSOL DISPERSIBLE®
Name Brukinsa® (zanubrutinib) capsules
Description

Brukinsa® (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor.

Indication Indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
 Strengths

80 mg capsules
Recommended dose:

  • The recommended dose of Brukinsa is 160 mg taken orally twice daily or 320 mg taken orally once daily.
 Regulatory Status

EMA approved in 2021; USFDA approved in 2019
Registered in Saudi Arabia and UAE

 Business Partner BeiGene
CAPHOSOL® CAPHOSOL DISPERSIBLE®